JP2023100904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023100904A5 JP2023100904A5 JP2023077666A JP2023077666A JP2023100904A5 JP 2023100904 A5 JP2023100904 A5 JP 2023100904A5 JP 2023077666 A JP2023077666 A JP 2023077666A JP 2023077666 A JP2023077666 A JP 2023077666A JP 2023100904 A5 JP2023100904 A5 JP 2023100904A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antidepressant
- use according
- ketamine
- antipsychotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000935 antidepressant agent Substances 0.000 claims 9
- 229940005513 antidepressants Drugs 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 230000001430 anti-depressive effect Effects 0.000 claims 6
- -1 Citryri) Chemical compound 0.000 claims 4
- 230000000561 anti-psychotic effect Effects 0.000 claims 3
- 229960003299 ketamine Drugs 0.000 claims 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 2
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 2
- RKHCTAKUYDTFHE-QMMMGPOBSA-N ly-156,735 Chemical compound C1=C(Cl)C(OC)=CC2=C1NC=C2[C@@H](C)CNC(C)=O RKHCTAKUYDTFHE-QMMMGPOBSA-N 0.000 claims 2
- 229960002296 paroxetine Drugs 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 229960002073 sertraline Drugs 0.000 claims 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 2
- 229960002263 vortioxetine Drugs 0.000 claims 2
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 1
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 1
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 claims 1
- IUVSEUFHPNITEQ-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]piperazine Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CN2CCN(CC2)C=2C=3OCCOC=3C=CC=2)=C1 IUVSEUFHPNITEQ-UHFFFAOYSA-N 0.000 claims 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 claims 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 claims 1
- ZRXBCXGGXCXHCB-UHFFFAOYSA-N 7-[4-[2-(2,4-difluorophenyl)ethyl]piperazine-1-carbonyl]-1h-indole-3-carbonitrile Chemical compound FC1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C=3NC=C(C=3C=CC=2)C#N)CC1 ZRXBCXGGXCXHCB-UHFFFAOYSA-N 0.000 claims 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 1
- RONZAEMNMFQXRA-INIZCTEOSA-N LSM-5894 Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-INIZCTEOSA-N 0.000 claims 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims 1
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims 1
- 229960002629 agomelatine Drugs 0.000 claims 1
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 229960002519 amoxapine Drugs 0.000 claims 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 claims 1
- 229960001210 brexpiprazole Drugs 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- 229960001653 citalopram Drugs 0.000 claims 1
- 229960004606 clomipramine Drugs 0.000 claims 1
- PSPGQHXMUKWNDI-UHFFFAOYSA-N coluracetam Chemical compound C=12C(C)=C(C)OC2=NC=2CCCCC=2C=1NC(=O)CN1CCCC1=O PSPGQHXMUKWNDI-UHFFFAOYSA-N 0.000 claims 1
- 229950000190 coluracetam Drugs 0.000 claims 1
- 229960005217 dapoxetine Drugs 0.000 claims 1
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 claims 1
- SRPXSILJHWNFMK-MEDUHNTESA-N dasotraline Chemical compound C1([C@@H]2CC[C@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-MEDUHNTESA-N 0.000 claims 1
- 229960003914 desipramine Drugs 0.000 claims 1
- 229960001623 desvenlafaxine Drugs 0.000 claims 1
- 229960002866 duloxetine Drugs 0.000 claims 1
- VAIOZOCLKVMIMN-PRJWTAEASA-N eplivanserin Chemical compound C=1C=CC=C(F)C=1\C(=N/OCCN(C)C)\C=C\C1=CC=C(O)C=C1 VAIOZOCLKVMIMN-PRJWTAEASA-N 0.000 claims 1
- 229950000789 eplivanserin Drugs 0.000 claims 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 1
- 229960004341 escitalopram Drugs 0.000 claims 1
- RONZAEMNMFQXRA-MRXNPFEDSA-N esmirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-MRXNPFEDSA-N 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229960004038 fluvoxamine Drugs 0.000 claims 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 1
- 229960004801 imipramine Drugs 0.000 claims 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical group C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 1
- 229950002473 indalpine Drugs 0.000 claims 1
- SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 claims 1
- 229940125425 inverse agonist Drugs 0.000 claims 1
- GJJFMKBJSRMPLA-DZGCQCFKSA-N levomilnacipran Chemical compound C=1C=CC=CC=1[C@]1(C(=O)N(CC)CC)C[C@H]1CN GJJFMKBJSRMPLA-DZGCQCFKSA-N 0.000 claims 1
- 229960000685 levomilnacipran Drugs 0.000 claims 1
- VOBHXZCDAVEXEY-JSGCOSHPSA-N lisdexamfetamine Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 VOBHXZCDAVEXEY-JSGCOSHPSA-N 0.000 claims 1
- 229960001451 lisdexamfetamine Drugs 0.000 claims 1
- 229960004090 maprotiline Drugs 0.000 claims 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims 1
- 229960003955 mianserin Drugs 0.000 claims 1
- 229960000600 milnacipran Drugs 0.000 claims 1
- 229960001785 mirtazapine Drugs 0.000 claims 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 1
- 229960001800 nefazodone Drugs 0.000 claims 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- RKEWSXXUOLRFBX-UHFFFAOYSA-N pimavanserin Chemical compound C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 239000002469 receptor inverse agonist Substances 0.000 claims 1
- RNRYULFRLCBRQS-UHFFFAOYSA-N roluperidone Chemical compound C1=CC(F)=CC=C1C(=O)CN1CCC(CN2C(C3=CC=CC=C3C2)=O)CC1 RNRYULFRLCBRQS-UHFFFAOYSA-N 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000002400 serotonin 2A antagonist Substances 0.000 claims 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 229950002275 setiptiline Drugs 0.000 claims 1
- GVPIXRLYKVFFMK-UHFFFAOYSA-N setiptiline Chemical compound C12=CC=CC=C2CC2=CC=CC=C2C2=C1CN(C)CC2 GVPIXRLYKVFFMK-UHFFFAOYSA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960003991 trazodone Drugs 0.000 claims 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 claims 1
- 229960003740 vilazodone Drugs 0.000 claims 1
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 claims 1
Claims (9)
- 外傷後ストレス障害（ＰＴＳＤ）又はその症状の治療における使用のための組成物であって、前記組成物が、
≧５００ｍｇ／ｄ～≦１０００ｍｇ／ｄの投与量で投与され、かつ２５マイクログラム（μｇ）／ｍＬを超える血中レベルをもたらすように配合されるＤ－サイクロセリンを含むことを特徴とする組成物。 - 抗うつ剤又は抗精神病剤を更に含む、請求項１に記載の使用のための組成物。
- 前記抗うつ剤が、四環系抗うつ剤（ＴｅＣＡ）、選択的セロトニン再取り込み阻害薬（ＳＳＲＩ）、セロトニン／ノルエピネフリン（ｎｏｒｅｐｈｉｎｅｐｈｒｉｎｅ）再取り込み阻害薬（ＳＮＲＩ）、ノルアドレナリン及び特異的セロトニン剤（ＮａＳＳａ）、非定型抗うつ剤、５－ＨＴ２Ａアンタゴニスト、及びこれらの組合せからなる群から選択される、請求項２に記載の使用のための組成物。
- 前記抗うつ剤又は前記抗精神病剤が、セルトラリン、パロキセチン、及びクエチアピンからなる群から選択される、請求項２に記載の使用のための組成物。
- 前記抗うつ剤が、イミプラミン、アミトリプチリン、アモキサピン、ブプロピオン、シタロプラム、クロミプラミン、デシプラミン、デスベンラファキシン、デュロキセチン、エスシタロプラム、フルオキセチン、フルボキサミン、レボミルナシプラン、マプロチリン、ミアンセリン、ミルナシプラン、ラセミ体ミルタザピン、Ｓ－（＋）－ミルタザピン、Ｒ－（－）－ミルタザピン、ネファゾドン、パロキセチン、セルトラリン、セチプチリン、トラゾドン、ベンラファキシン、ベンラファキシンＸＲ、ダポキセチン、インダルピン（ｉｎｄａｌｐｉｎｅ）、ビラゾドン、及びボルチオキセチンからなる群から選択される、請求項２に記載の使用のための組成物。
- 前記抗うつ剤又は前記抗精神病剤が、選択的５－ＨＴ２Ａ受容体アンタゴニスト又はインバースアゴニストである、請求項２に記載の使用のための組成物。
- 前記抗うつ剤又は前記抗精神病剤が、ボリナンセリン（ＭＤＬ１００，９０７）、プルバンセリン（ＥＭＤ２８１０１４）、エプリバンセリン（ＳＲ－４６３４９、Ｃｉｔｒｙｒｉ）、ＣＹＲ－１０１ ピマバンセリン（ＡＣＰ－１０３）、アゴメラチン、Ｌｕ ＡＡ２１００４、Ｆ２６９５、ＳＥＰ－２２７１６２、ＬｕＡＡ２４５３０、ＳＥＰ－２２５２８９、ＬＹ１２６２４８０３、ＨＹ１０２７５、ＴＩＫ－３０１／ＬＹ１５６７３５、ロナセン、ＬＵ－３１－１３０、ＳＬＶ３１３、エディボキセチン、ＯＰＣ－３４７１２、リスデキサンフェタミン、サコメリン（ｓａｃｏｍｅｌｉｎｅ）、コルラセタム（ｃｌｏｕｒａｃｅｔａｍ）、及びＢＭＳ－８２０３６からなる群から選択される、請求項２に記載の使用のための組成物。
- 前記Ｄ－サイクロセリン及び前記抗うつ剤の投与の前に、対象に非経口的にケタミン、Ｓ－ケタミン、又はＲ－ケタミンを投与することを更に含む、請求項２に記載の使用のための組成物。
- 前記ケタミンが、静脈内に、鼻腔内に、又は皮下に投与される、請求項８に記載の使用のための組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510801P | 2017-05-25 | 2017-05-25 | |
| US62/510,801 | 2017-05-25 | ||
| US201762518020P | 2017-06-12 | 2017-06-12 | |
| US62/518,020 | 2017-06-12 | ||
| JP2019564988A JP7312116B2 (ja) | 2017-05-25 | 2018-05-24 | 外傷後ストレス障害の治療用の製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564988A Division JP7312116B2 (ja) | 2017-05-25 | 2018-05-24 | 外傷後ストレス障害の治療用の製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023100904A JP2023100904A (ja) | 2023-07-19 |
| JP2023100904A5 true JP2023100904A5 (ja) | 2023-08-30 |
| JP7537675B2 JP7537675B2 (ja) | 2024-08-21 |
Family
ID=64396350
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564988A Active JP7312116B2 (ja) | 2017-05-25 | 2018-05-24 | 外傷後ストレス障害の治療用の製剤 |
| JP2019564867A Active JP7308761B2 (ja) | 2017-05-25 | 2018-05-24 | Ｎｍｄａｒアンタゴニスト－応答性精神神経障害のための併用療法 |
| JP2023034164A Pending JP2023071900A (ja) | 2017-05-25 | 2023-03-07 | Ｎｍｄａｒアンタゴニスト－応答性精神神経障害のための併用療法 |
| JP2023077666A Active JP7537675B2 (ja) | 2017-05-25 | 2023-05-10 | 外傷後ストレス障害の治療用の製剤 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564988A Active JP7312116B2 (ja) | 2017-05-25 | 2018-05-24 | 外傷後ストレス障害の治療用の製剤 |
| JP2019564867A Active JP7308761B2 (ja) | 2017-05-25 | 2018-05-24 | Ｎｍｄａｒアンタゴニスト－応答性精神神経障害のための併用療法 |
| JP2023034164A Pending JP2023071900A (ja) | 2017-05-25 | 2023-03-07 | Ｎｍｄａｒアンタゴニスト－応答性精神神経障害のための併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10881665B2 (ja) |
| EP (1) | EP3630102B1 (ja) |
| JP (4) | JP7312116B2 (ja) |
| KR (2) | KR102654569B1 (ja) |
| CN (2) | CN110996947A (ja) |
| AU (2) | AU2018274767A1 (ja) |
| BR (2) | BR112019024802A2 (ja) |
| CA (2) | CA3064846A1 (ja) |
| IL (2) | IL270885B2 (ja) |
| MX (2) | MX2019014113A (ja) |
| RU (2) | RU2019143573A (ja) |
| WO (2) | WO2018216018A1 (ja) |
| ZA (2) | ZA201908616B (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019024802A2 (pt) * | 2017-05-25 | 2020-07-21 | Glytech Llc. | terapia combinada para transtornos neuropsiquiátricos responsivos ao antagonista de nmdar |
| CN118453559A (zh) | 2018-02-15 | 2024-08-09 | 国立大学法人千叶大学 | 炎症性疾病或骨病的预防或治疗剂及医药组合物 |
| US11426367B2 (en) | 2018-05-04 | 2022-08-30 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| US20210386689A1 (en) * | 2018-10-31 | 2021-12-16 | Sunovion Pharmaceuticals Inc. | Methods of treating central nervous system disorders |
| JP2022526427A (ja) * | 2019-04-09 | 2022-05-24 | ヴィスタゲン セラピューティクス、インコーポレイテッド | 神経障害の治療への反応に関連する遺伝的変異体 |
| JP2023509484A (ja) * | 2020-01-03 | 2023-03-08 | ユニバーシティ オブ パドヴァ | 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン |
| CN115677519A (zh) * | 2021-07-22 | 2023-02-03 | 立科时代(武汉)生物科技有限公司 | L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用 |
| CN113648320A (zh) * | 2021-08-16 | 2021-11-16 | 中国人民解放军军事科学院军事医学研究院 | 赛洛西宾抗创伤后应激障碍的医药用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| EP2338482A3 (en) | 1998-04-14 | 2011-12-21 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
| WO2005016319A2 (en) * | 2003-08-06 | 2005-02-24 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| MXPA05007568A (es) | 2003-01-16 | 2005-09-21 | Acadia Pharm Inc | Agonistas inversos del receptor selectivo de serotonina 2a/2c como terapeuticos para enfermedades neurodegenerativas. |
| US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| CA2556216A1 (en) | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| PL2289879T3 (pl) | 2004-09-27 | 2015-05-29 | Acadia Pharm Inc | Synteza formy krystalicznej soli winianowej n-(4-fluorobenzylo)-n-(1-metylopiperydyn-4-ylo)-n'-(4-(2-metylopropyloksy)fenylometylo)karbamidu |
| TW200631584A (en) | 2004-11-15 | 2006-09-16 | Akzo Nobel Nv | A medicament related to mirtazapine for the treatment of hot flush |
| EP2099444A4 (en) | 2006-12-14 | 2012-11-07 | Nps Pharma Inc | USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| ES2673956T3 (es) * | 2011-01-31 | 2018-06-26 | Serotech, Llc | Régimen de dosificación, envase de dispensación de la medicación y usos de los mismos para el tratamiento del trastorno depresivo mayor |
| EP2841063A2 (en) | 2012-04-27 | 2015-03-04 | Indiana University Research and Technology Corporation | Compositions and methods for treating ptsd and related diseases |
| RS60556B1 (sr) * | 2013-10-18 | 2020-08-31 | Emalex Biosciences Inc | Kondenzovani benzazepini za lečenje mucanja |
| EP3197440A4 (en) | 2014-09-22 | 2018-04-18 | Rugen Holdings (Cayman) Limited | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016061320A2 (en) * | 2014-10-15 | 2016-04-21 | Rowan University | Timber therapy for post-traumatic stress disorder |
| AU2016303610A1 (en) | 2015-08-04 | 2018-02-01 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and D-cycloserine |
| BR112019024802A2 (pt) * | 2017-05-25 | 2020-07-21 | Glytech Llc. | terapia combinada para transtornos neuropsiquiátricos responsivos ao antagonista de nmdar |
-
2018
- 2018-05-24 BR BR112019024802-1A patent/BR112019024802A2/pt unknown
- 2018-05-24 MX MX2019014113A patent/MX2019014113A/es unknown
- 2018-05-24 BR BR112019024817-0A patent/BR112019024817A2/pt active Search and Examination
- 2018-05-24 JP JP2019564988A patent/JP7312116B2/ja active Active
- 2018-05-24 RU RU2019143573A patent/RU2019143573A/ru not_active Application Discontinuation
- 2018-05-24 RU RU2019143572A patent/RU2019143572A/ru not_active Application Discontinuation
- 2018-05-24 CN CN201880048653.3A patent/CN110996947A/zh active Pending
- 2018-05-24 EP EP18805411.8A patent/EP3630102B1/en active Active
- 2018-05-24 MX MX2019014114A patent/MX2019014114A/es unknown
- 2018-05-24 AU AU2018274767A patent/AU2018274767A1/en not_active Abandoned
- 2018-05-24 WO PCT/IL2018/050567 patent/WO2018216018A1/en active Application Filing
- 2018-05-24 KR KR1020197038205A patent/KR102654569B1/ko active IP Right Grant
- 2018-05-24 CN CN201880048442.XA patent/CN110996946A/zh active Pending
- 2018-05-24 CA CA3064846A patent/CA3064846A1/en active Pending
- 2018-05-24 US US15/987,933 patent/US10881665B2/en active Active
- 2018-05-24 WO PCT/IL2018/050570 patent/WO2018216020A1/en active Application Filing
- 2018-05-24 CA CA3065003A patent/CA3065003A1/en active Pending
- 2018-05-24 AU AU2018274765A patent/AU2018274765A1/en not_active Abandoned
- 2018-05-24 US US15/987,941 patent/US20180338956A1/en not_active Abandoned
- 2018-05-24 JP JP2019564867A patent/JP7308761B2/ja active Active
- 2018-05-24 KR KR1020197038209A patent/KR102608479B1/ko active IP Right Grant
- 2018-05-24 IL IL270885A patent/IL270885B2/en unknown
-
2019
- 2019-11-25 IL IL270916A patent/IL270916A/en unknown
- 2019-12-23 ZA ZA2019/08616A patent/ZA201908616B/en unknown
- 2019-12-23 ZA ZA2019/08617A patent/ZA201908617B/en unknown
-
2021
- 2021-01-01 US US17/139,999 patent/US11969431B2/en active Active
-
2022
- 2022-01-28 US US17/586,828 patent/US20220143041A1/en active Pending
-
2023
- 2023-03-07 JP JP2023034164A patent/JP2023071900A/ja active Pending
- 2023-05-10 JP JP2023077666A patent/JP7537675B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023100904A5 (ja) | ||
| RU2019143572A (ru) | Композиции для лечения посттравматического стрессового расстройства | |
| US20090306137A1 (en) | Treatment for depressive disorders | |
| JP2009538331A5 (ja) | ||
| RU2012152922A (ru) | Лечение психологических состояний с применением антагонистов м1-мускариновых рецепторов | |
| JP2012036212A5 (ja) | ||
| JP2009542819A5 (ja) | ||
| JP2013079277A (ja) | ムスカリン性受容体ｍ１拮抗薬による肥満の処置 | |
| JP2007513052A5 (ja) | ||
| JP2009542820A5 (ja) | ||
| CN101472476B (zh) | 毒蕈碱型受体m1拮抗剂在制备治疗肥胖症的药物中的应用 | |
| WO2004100938A1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| RU2009101146A (ru) | Лечение ожирения антагонистами мускаринового рецептора м1 | |
| JP2007513896A5 (ja) | ||
| MX2009001219A (es) | Composicion farmaceutica que contiene en combinacion saredutant y un inhibidor selectivo de recaptacion de serotonina o un inhibidor de recaptacion de serotonina/norepinefrina. | |
| RU2019123563A (ru) | Новые комбинации антагонистов н3-рецепторов и ингибиторов обратного захвата норадреналина и их терапевтическое применение | |
| US20080182899A1 (en) | Association of beta3 receptor agonist and monoamine reuptake inhibitors, pharmaceutical composition and therapeutic use thereof |